Jan 09 approvals

USA>>
- Forest Labs> Savella (milnacipran hydrochloride): Fibromyalgia
- Galderma Labs> Vectical (calcitrol): B3 ointment for plaque psoriasis
- Watson> Gelnique (oxybutynin chloride): Gel for overactive bladder (OAB)
- Takeda> Kapidex (dexlansoprazole): Erosive esophagitis

Canada>>
- Alexion> *Soliris (eculizumab): Paroxysmal nocturnal hemoglobinuria (PNH)
- Biovitrium> Kineret (anakinra): Rheumatoid arthritis
- Biovitrum> Stemgen (ancestim): Supportive oncology
- Biovitrum> Kepivance (palifermin): Supportive oncology
- Bayer> Helixate FS & Kogenate FS: Spontaneous hemorhagic episodes & prevention of joint damage in children
- Bausch & Lomb> Lotemax (loteprednol etabonate): Opthalmic corticosteroid
- Paladin> Trinipatch (nitroglycerin): Anti-anginal
- BMS> Reyataz (atazanavir): Treatment naive HIV
- CSL Behring> Humate-P: Von Willebrand disease, excess bleeding
- ScheringPlough> Deca-Durabolin (nandrolone): Anabolic androgen
- ScheringPlough> Andriol (testosterone): Anabolic androgen

Japan>>
- Novartis> Xolair (olabizumab): Bronchial Asthma
- Novartis> Tasigna (nilotimib): Philadelphia chromosome-positive chronic myeloid leukemia
- Novartis> Diovan (valsartan/hydrochlorothiazide combi): blood pressure
- Novartis> Lucentis (ranibizumab): Wet macular degeneration

EU>>
-Janssen Cilag/J&J> Stelara (ustekinumab): Moderate to severe plaque psoriasis

*Priority review drug